About the Company
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
106
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CNST News
Constellation Pharmaceuticals gets grant for novel compounds for treating diseases associated with methyl modifying enzymes
Discover how Constellation Pharmaceuticals Inc's patented compounds are revolutionizing cancer treatment. Learn about the versatile applications and potential for treating various types of cancer.
Constellation Brands Inc Class A STZ
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Stocks to Watch Thursday: Robinhood, Alpine Immune, Constellation Brands
The biotech firm agreed to acquire Alpine Immune Sciences (ALPN) for $4.9 billion to bolster its kidney-disease portfolio. In off-hours trading, Alpine's shares soa ...
Constellation Software Inc.
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
Constellation Software Inc., Topicus.com Inc. and Lumine Group Inc. Announce Annual Meetings
The Constellation Software Inc. (“Constellation” or “CSI”) (TSX:CSU) annual meeting of shareholders will be held on Monday, May 13, 2024 at 9:00 a.m. EST using a virtual meeting format ...
Constellation Software Inc. Announces Release Date for First Quarter Results
TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) announced today it intends to release its first quarter results on May 10, 2024. The Company’s quarterly results ...
Plc Gsk's Net Worth
Plc Gsk has an estimated net worth of $9.11 Billion. This is based on reported shares across multiple companies, which include Wave Life Sciences Ltd., CVRx, Inc., Lyell Immunopharma, Inc ...
Rocket Lab launches NASA's solar sail technology into orbit
Rocket Lab's Electron launched NASA's new composite solar sail into space where it will undergo weeks of testing, using sunlight to propel it through the solar system.
Constellation Brands, Inc. (STZ)
VICTOR, N.Y., April 18, 2024 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that its indirect, wholly ...
Constellation Brands Inc - Class A
Constellation Brands Inc is a leading beverage company, known for its wide range of beer, wine, and spirits. With popular beer brands like Corona and Modelo, and wine and spirits labels such as ...
Loading the latest forecasts...